Paolo Ciracì
@p_ciracimd
Followers
2K
Following
1K
Media
51
Statuses
494
Medical Oncology Resident at the University Hospital of Pisa, Italy. Focused on clinical and translational research on gastrointestinal cancers.
Pisa
Joined December 2021
#ESMOGI25 was an incredible experience — truly honored to present results from the PARERE study by @FoundationGono in the Proffered Session
1
4
25
RT @myESMO: 📣 ESMO Living Guidelines on Metastatic Colorectal Cancer v1.3: Updated recommendations and algorithms for the treatment of pati….
0
16
0
RT @ACCMEDorg: YOUNG TO YOUNG @ ESMO GI 2025.. Le interviste "live" realizzate dagli inviati di Young to Young dura….
0
4
0
RT @Medi_Mix: 🎥 #ESMOGI2025 Highlight! Dr @PJCuyle discusses key advances in mCRC:.✔️ ctDNA surveillance increases curative-intent treatmen….
0
3
0
RT @myESMO: #ESMOGI25: Randomised #ClinicalTrials and real-world studies in #mCRC provide further evidence in favour of anti-EGFR rechallen….
0
1
0
RT @Larvol: Recap of Day 3 of ESMO - European Society for Medical Oncology Gastrointestinal (GI) Cancers Congress 2025: Top Trials. Explore….
0
11
0
RT @Erman_Akkus: 📢Proffered paper #ESMOGI25 @myESMO. ➡️PARERE trial, mCRC.➡️ctDNA guided anti-EGFR rechallenge.✅May detect new developed RA….
0
7
0
RT @MarioBalsaMD: 💥 Proffered paper #ESMOGI25 - PARERE trial: ctDNA-guided sequencing in RAS/BRAF wt mCRC. 💉Panitumumab re-treatment (vs re….
0
8
0
RT @Erman_Akkus: ⚖️Full publication of LEANOX Trial.@JCO_ASCO . ➡️Lean Body Mass–Based vs body-surface area Oxaliplatin Dose Calculation in….
0
24
0
RT @Erman_Akkus: 💉Liver-Directed Therapies in CRC.@ASCO Educational book . ✅HAI, ablation, TARE, SBRT, transplantation. 👉.
0
27
0
RT @Erman_Akkus: Are Early-Onset Cancers an Example of Accelerated Biological Aging? | Oncology | JAMA Oncology | JAMA Network https://t.co….
jamanetwork.com
This Viewpoint describes accelerated biological aging as a potential mechanism by which exposures lead to early-onset cancers.
0
7
0
RT @CathyEngMD: @ChiaraCrem1 presenting PARERE phase 2 trial on the role of #ctDNA guided re-tx with PMab prolongs PFS #cancer #CancerResea….
0
1
0
RT @AIOMtweet: Un'intervista da #ASCO25 a Chiara Cremolini, dell'Unità di Oncologia Medica 2, AOU Pisana e Dipartimento di Ricerca Traslazi….
0
2
0
First results from the PARERE trial by @FoundationGono .🩸RAS and BRAF ctDNA muts: >1/3 of mCRC patients eligible for anti-EGFR re-treatment.➡️ pani re-tx was associated with higher ORR, DCR, and longer PFS independently of the treatment sequencing. @ChiaraCrem1 #ASCO25.@ASCO
0
3
6
Updated results from the phase 3 TRIPLETE study by @FoundationGono . ➡️ Upfront mFOLFOXIRI plus panitumumab resulted in a longer OS of 41.1 vs 33.3 mos (FOLFOX/pan) .➡️ no significant difference in PFS and ORR was confirmed . @VeroKonk #ASCO25 .@ASCO
0
3
12
RT @AndreaCercek: Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Jo….
nejm.org
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...
0
38
0